Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.
SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Note: The words woman/women/mother/she/her have been used throughout this guideline as most pregnant and birthing people identify with their birth sex. However, for the purpose of this guideline, these terms include people who do not identify as women or mothers, including those with a non-binary identity. All clinicians should ask the pregnant person what their preferred term is and ensure this is communicated to the healthcare team.

Explanation of the aboriginal artwork:
The Aboriginal artwork used symbolises the connection to country and the circle shape shows the strong relationships amongst families and the Aboriginal culture. The horse shoe shape design shown in front of the generic statement symbolises a woman and those enclosing a smaller horse shoe shape depicts a pregnant woman. The smaller horse shoe shape in this instance represents the unborn child. The artwork shown before the specific statements within the document symbolises a footprint and demonstrates the need to move forward together in unison.

Purpose and Scope of Perinatal Practice Guideline (PPG)
Guidance for the management of Preterm Pre-labour Rupture of Membranes (PPROM).
For additional information and management of preterm labour, see the Preterm Labour and Birth, Prevention, Diagnosis & management PPG.
Flowchart 1 | Assessment and Management of Preterm Prelabour Rupture of Membranes (PPROM)

**PPROM / Preterm labour assessment**
- Clinical signs of PPROM
- Vaginal loss - note amount, colour, any odour
- back pain
- vaginal spotting or "show"
- regular uterine activity

**Investigations**
- CRP & CBP
- MSU
- Ultrasound - assess liquor volume and cervical length

**Physical examination**
- vital signs
- abdominal examination
- fetal heart rate +/- CTG

**Sterile speculum examination**
- exclude cord prolapse
- visualise pooling of liquor
- take high & low vaginal swabs
- obtain amn & check for ferning
- estimate cervical dilatation
- remove cervical suture if present

**No evidence PPROM**

**PPROM confirmed**

**PPROM not confirmed but good history**

**PPROM confirmed**

+/- Threatened preterm labour

No signs of choioamnionitis

**Suppress / expectant management**

+ tocolysis (if contracting)
+ close observation
+ admit & offer analgesia
+ administer steroids (< 34+6 weeks gestation)
+ commence prophylactic antibiotics for GBS
+ transfer as required if delivery not imminent

**Outpatient management**

+Consider home care with outpatient management if stable

**Outpatient management**

+ instruct the woman to take her temperature daily
+ observe PV loss
+ return for twice weekly CTG and CBP & CRP
+ weekly IVG (results may guide use of antibiotics in any subsequent labour)
+ Return to hospital if reduced fetal movements

**Active preterm labour?**

No

Yes

**Active preterm labour**

Gestation > 26 weeks

Evidence of intrauterine infection

**Active management**

+ administer steroids < 34 weeks gestation (if not already given)
+ prophylactic antibiotics for GBS (if not already given)
+ start triple antibiotics if signs of infection
+ MgSO4 neuroprotection if at least 24h and < 30 weeks of gestation (delivery expected < 24 hours)
+ continuous fetal monitoring with CTG (depending on gestation)

**Management as in Preterm labour**

+ consult with Obstetrician re mode of delivery
+ Paediatrician review

**Delivery does not occur**

+ further benzylpenicillin when labour recurs

**Supplemental information**

- Home
- Sterile speculum examination
- Physical examination
- Flowchart 1 | Assessment and Management of Preterm Prelabour Rupture of Membranes (PPROM)
- PPROM / Preterm labour assessment
- Investigations
- Physical examination
- Sterile speculum examination

**Government of South Australia
SA Health**
Table of Contents

Purpose and Scope of Perinatal Practice Guideline (PPG) .......................................................... 1
Preterm Prelabour Rupture of Membranes .................................................................................. 2
Flowchart 1 | Assessment and Management of Preterm Prelabour Rupture of Membranes (PPROM) ... 2
Preterm Prelabour Rupture of Membranes .................................................................................. 4
Abbreviations .............................................................................................................................. 4
Introduction ..................................................................................................................................... 4
Definition ......................................................................................................................................... 4
Associated risks of PPROM ........................................................................................................... 4
Preterm Prelabour Rupture of Membranes .................................................................................. 5
Initial Assessment .......................................................................................................................... 5
Transfer or retrieval for access to specialised obstetric and neonatal services ............................ 5
Surveillance / Fetal assessment ...................................................................................................... 5
Laboratory investigations .............................................................................................................. 5
Antibiotic prophylaxis .................................................................................................................... 5
Preterm Prelabour Rupture of Membranes .................................................................................. 6
Signs of Chorioamnionitis ............................................................................................................. 6
If there are signs of chorioamnionitis ............................................................................................ 6
Preterm Prelabour Rupture of Membranes .................................................................................. 7
Preterm Prelabour Rupture of Membranes .................................................................................. 8
Magnesium sulphate for neuroprotection of the fetus .................................................................. 8
Controlled trials ............................................................................................................................. 8
Indications ....................................................................................................................................... 8
Dosage and administration ............................................................................................................ 8
Counselling ...................................................................................................................................... 8
Preterm Prelabour Rupture of Membranes .................................................................................. 9
Management ................................................................................................................................. 9
PPROM < 23 weeks gestation ......................................................................................................... 9
PPROM 23-34 weeks gestation ..................................................................................................... 9
Preterm Prelabour Rupture of Membranes .................................................................................. 10
Preterm Prelabour Rupture of Membranes .................................................................................. 11
Preterm Prelabour Rupture of Membranes .................................................................................. 12
References ...................................................................................................................................... 12
Preterm Prelabour Rupture of Membranes .................................................................................. 13
Acknowledgements ....................................................................................................................... 13
Document Ownership & History ................................................................................................... 14
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CTG</td>
<td>Cardiotocography</td>
</tr>
<tr>
<td>et al.</td>
<td>And others</td>
</tr>
<tr>
<td>g</td>
<td>Gram(s)</td>
</tr>
<tr>
<td>&gt;</td>
<td>Greater than</td>
</tr>
<tr>
<td>GBS</td>
<td>Group B Streptococcus</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>kg</td>
<td>Kilogram/s</td>
</tr>
<tr>
<td>&lt;</td>
<td>Less than</td>
</tr>
<tr>
<td>mL</td>
<td>Millilitre(s)</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram(s)</td>
</tr>
<tr>
<td>PPROM</td>
<td>Preterm prelabour of the membranes</td>
</tr>
<tr>
<td>i.e.</td>
<td>That is</td>
</tr>
</tbody>
</table>

### Introduction

> PPROM complicates only 2% of pregnancies but is associated with 40% of preterm deliveries and can result in significant neonatal morbidity and mortality

> The three causes of neonatal death associated with PPROM are:

  - Prematurity
  - Sepsis
  - Pulmonary hypoplasia

> Outcomes for preterm infants depend on place of birth and access to neonatal intensive care. Maternal transfer is generally safer than neonatal retrieval if delivery is not imminent.

### Definition

> Rupture of the fetal membranes before 37\(^{+0}\) completed weeks of pregnancy (i.e. preterm) and before the onset of labour (i.e. prelabour).

### Associated risks of PPROM

> Preterm labour
> Cord prolapse
> Placental abruption
> Intrauterine infection / amnionitis
> Pulmonary hypoplasia
> Limb positioning defects
> Perinatal mortality
Initial Assessment

> History and examination
> Abdominal palpation to determine fetal size and presentation
> Speculum examination to:
  - Exclude cord prolapse
  - Visualise pooling of liquor (note presence of vernix)
  - Collect cervical and vaginal microbiological swabs (including GBS)
  - Estimate cervical dilatation

Use available testing modality to confirm ROM:
  - Amnicator (nitrazine yellow): a positive reaction results in a blue / purple colour on contact (false positive rate of 17 %)
  - Make a smear to look for ferning on microscopical examination
  - Actim®PROM, AmniSure®, ROMPlus®

Transfer or retrieval for access to specialised obstetric and neonatal services

> In units without neonatal facilities suitable for the gestation, consult with tertiary centre. Consider maternal transfer if delivery is not imminent or consult with neonatal retrieval service if delivery is anticipated

Surveillance / Fetal assessment

> Cardiotocography (CTG) to assess fetal condition
> Ultrasound to assess liquor volume (and visualise presentation)
> Consider formal ultrasound for fetal number, weight, presentation, morphology and liquor volume

Laboratory investigations

> C-Reactive Protein – repeat daily for three days
> Complete blood picture – repeat daily for three days
> Low and high vaginal swabs for microscopy and culture
> Midstream specimen of urine for bacteriology

Antibiotic prophylaxis

> Studies show that prophylactic antibiotics prolong pregnancy and reduce maternal and neonatal sepsis (Kenyon et al. 2003)

Refer to Antibiotics in the Peripartum Period PPG for guidance on most appropriate antibiotic choice for the individual woman.
Signs of Chorioamnionitis

> The diagnosis of chorioamnionitis relies on the clinical presentation and may be difficult in its early manifestations.

> The clinical picture may include **maternal fever** with two or more of the following:

  > Increased white cell count (> 15 x 10^9 / L)
  > Maternal tachycardia (> 100 bpm)
  > Fetal tachycardia (>160 bpm)
  > Uterine tenderness
  > Offensive smelling vaginal discharge
  > C-Reactive Protein > 40

> Consideration should also be given to check for any other site of infection (e.g. urinary or respiratory tract) which could cause these changes.

> If in doubt consultation with a senior obstetrician, maternal fetal medicine or infectious disease physician should be considered.

> Histological examination of placenta and membranes with evidence of acute inflammation may confirm the diagnosis after birth.

If there are signs of chorioamnionitis

> Do not inhibit labour, but consider hastening delivery under intravenous antibiotic cover.

> Consider optimal mode of delivery (LSCS versus vaginal birth) on the basis of the findings and the anticipated duration until birth.

Tocolytics

> Where contractions are present, nifedipine may be commenced (for further information see ‘nifedipine for preterm labour’ in the A to Z index at [www.sahealth.sa.gov.au/perinatal](http://www.sahealth.sa.gov.au/perinatal)) to prolong pregnancy for 48 hours while corticosteroid cover is established if there are no other signs of chorioamnionitis.

  > Give stat oral dose nifedipine 20 mg

  > Give second oral dose nifedipine 20 mg 30 minutes after first dose (maximum is 40 mg in the first hour)

  > Do not give any further nifedipine until 3 hours after the 2nd dose.

  > Administer oral nifedipine 20 mg every 3 hours until contractions cease or the woman establishes in labour. Prescribe as written (do not prescribe as prn).

  > After 24 hours, medical review is required to determine the dose of maintenance treatment with controlled release nifedipine (Adalat® Oros) 2-3 times per day.

> For further information see ‘nifedipine for preterm labour’ in the A to Z index at [www.sahealth.sa.gov.au/perinatal](http://www.sahealth.sa.gov.au/perinatal)
## Corticosteroids

<table>
<thead>
<tr>
<th>Indications</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age is between 23-0 and 34-6 weeks and in PTL</td>
<td>Administer IM betamethasone in two doses of 11.4 mg (5.7 mg x 2) 24 hours apart to the woman</td>
</tr>
<tr>
<td>Risk of preterm imminent birth</td>
<td>If betamethasone is unavailable, give IM dexamethasone in two doses of 12 mg, 24 hours apart</td>
</tr>
<tr>
<td>Preterm birth is planned or expected within the next seven days</td>
<td>Where appropriate, estimate the risk of preterm birth by considering the use of adjunct prediction tests including fetal fibronectin and assessment of cervical length</td>
</tr>
</tbody>
</table>

### Single course

### Repeat course(s)

<table>
<thead>
<tr>
<th>Indications</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>When the gestational age is 32-6 days or less</td>
<td>Either: A single repeat dose of IM betamethasone 11.4 mg IM (5.7 mg x 2) OR A single repeat course of IM betamethasone in two doses of 11.4 mg (5.7 mg x 2) 24 hours apart</td>
</tr>
<tr>
<td>OR A single repeat course of IM betamethasone in two doses of 11.4 mg (5.7 mg x 2) 24 hours apart</td>
<td>If betamethasone is unavailable, give IM dexamethasone 12 mg</td>
</tr>
</tbody>
</table>

### Further repeat single dose(s)

<table>
<thead>
<tr>
<th>Indications</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seven days after the first, single, repeat dose (and less than 14 days since the first repeat dose), if the woman is still considered to be at risk of preterm birth within the next seven days, a further, single, repeat dose of antenatal corticosteroids (IM betamethasone 11.4 mg IM [5.7 mg x 2]) can be given</td>
<td>Use up to a maximum of three, single, repeat doses only</td>
</tr>
<tr>
<td>OR A single repeat course of IM betamethasone in two doses of 11.4 mg (5.7 mg x 2) 24 hours apart</td>
<td>NB: Do not give any further repeat courses if a single repeat course (11.4 mg, as two intramuscular doses, 24 hours apart) of betamethasone has been given already</td>
</tr>
</tbody>
</table>
Magnesium sulphate for neuroprotection of the fetus

Controlled trials

> Show that fetal exposure to magnesium sulphate given before preterm birth has a neuroprotective role. The number of women needed to be treated to benefit one baby by avoiding cerebral palsy is 63 (Doyle et al. 2009)

> This systematic review also showed a significant reduction in the rate of gross motor dysfunction in early childhood (Doyle et al. 2009)

Indications

> Neuroprotection of the fetus for women at risk of preterm birth who are at least 24+0 weeks of gestation and < 30+0 weeks of gestation

> When birth is anticipated within 24 hours or in cases of expected planned delivery as close to four hours before expected delivery time and regardless of:
  > plurality
  > why the woman is at risk of preterm birth
  > parity
  > anticipated mode of birth
  > whether antenatal corticosteroids have been given or not

Dosage and administration

> See Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus in the A to Z index at www.sahealth.sa.gov.au/perinatal

Counselling

> The woman and her partner should be counselled by a member of the management team, which includes: obstetrician, neonatologist, midwife, and others as appropriate
Management

PPROM < 23 weeks gestation
> Outcomes for extremely preterm infants depend on place of birth and access to neonatal intensive care
> It is important to consult with neonatologists for up to date data to inform clinical decision making
> Parental attitudes must be taken into account in formulating a management plan
> Continue antibiotic prophylaxis (as above)

Active management (i.e. allow / encourage birth to proceed) when
> In established labour
> Signs of chorioamnionitis are present
> Significant antepartum haemorrhage is present
> The woman requests it

Expectant management
> Is acceptable when the risk of amnionitis and pulmonary hypoplasia is less than the risk of extreme preterm birth and neonatal death
> If delivery does not occur, further benzylpenicillin prophylaxis is indicated when labour recurs
> Repeat high vaginal swab at weekly intervals; results may guide use of antibiotics in any subsequent labour
> Complete blood picture and C-Reactive Protein twice weekly

PPROM 23-34 weeks gestation
> Continue antibiotic prophylaxis (as above)
> Expectant management until 34 weeks of gestation if GBS positive

Active management (i.e. allow / encourage birth to proceed) when
> In established labour
> Signs of chorioamnionitis are present
> Significant antepartum haemorrhage is present
> Signs of fetal compromise
> Consider caesarean section if birth is not imminent

Expectant management
> May be appropriate in the absence of the above. This management should include:
> Daily medical clinical assessment of the woman
> Clinical observations twice daily
> Temperature, maternal pulse, fetal heart rate
> PV loss
> Assessment of uterine activity (abdominal pain or tenderness)
> Involving a neonatologist
> If delivery does not occur, further benzylpenicillin prophylaxis is indicated when labour recurs
> Facilitating education including:
  > Neonatology review
  > Neonatal intensive care tour
  > Appropriate preterm birth DVD / video

Surveillance / fetal assessment
> CTG daily for the first 3-6 days, then twice per week if low risk inpatient or at home
> CTG should be reconsidered where regular fetal surveillance is required (RCOG 2006)
> Recomence CTG in the presence of:
  > Regular abdominal pains or tenderness
  > change in amount, colour of liquor
  > Antepartum haemorrhage

Investigations
> Complete blood picture (CBP), C- reactive protein (CRP) daily for 3 days
> Consecutive daily CRP values > 20 mg / L or isolated values > 40 mg / L are suggestive of infection
> Twice weekly after initial assessment

Vaginal swabs
> Repeat high vaginal swab at weekly intervals; results may guide use of antibiotics in any subsequent labour

PPROM at 34-37 weeks gestation
> Continue antibiotic prophylaxis (see above)
> Studies are currently in progress to establish whether to recommend expectant or active management for women with PPROM between 34 to 36 completed weeks of gestation

Active management (i.e. allow / encourage birth to proceed) when
> In established labour
> Signs of chorioamnionitis are present
> Significant antepartum haemorrhage is present
> If GBS positive, active management after 36 completed weeks of gestation
> Signs of fetal compromise
  > Consider caesarean section if birth is not imminent

**Expectant management consists of**
> Await spontaneous onset of labour until 36 completed weeks of gestation
> Continue prophylactic antibiotic treatment
> Home care may be considered

**Surveillance / fetal assessment**
> CTG daily for the first 3-6 days, then twice per week if low risk inpatient or at home
> CTG should be reconsidered where regular fetal surveillance is required (RCOG 2006)
> Recomence CTG in the presence of:
  > Regular abdominal pains or tenderness
  > change in amount, colour of liquor
  > Antepartum haemorrhage

**Home care**
> May be considered for all women after 72 hours of initial hospitalisation if:
  > Singleton pregnancy
  > Cephalic presentation > 23 weeks
  > Easy access to the hospital

**Continue**
> Daily temperature
> Twice weekly follow up CTG and investigations as an outpatient
> Return to hospital if reduced fetal movements
References


Acknowledgements

The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

SAPPG Management Group Members
Sonia Angus
Lyn Bastian
Dr Elizabeth Beare
Elizabeth Bennett
Dr Feisal Chenia
John Coomblas
Dr Danielle Crosby
Dr Scott Morris
Dr Ray Farley
Allison Waldron
Dr Charlotte Taylor
Rosina Gergis
Dr Anupam Parange
Marnie Aldred
Dr Michael McEvoy
Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: HealthCYWHSPerinatalProtocol@sa.gov.au
Endorsed by: Domain Custodian, Clinical Governance, Safety and Quality
Next review due: 07/09/20
ISBN number: 978-1-76083-573-6
PDS reference: PPG022
Policy history:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/08/22</td>
<td>V10.1</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td>New template Change in Antibiotic Prophylaxis. Removed and referred to Peripartum Antibiotics PPG.</td>
</tr>
<tr>
<td>7/09/15</td>
<td>V10</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed</td>
</tr>
<tr>
<td>20/05/14</td>
<td>V9</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed</td>
</tr>
<tr>
<td>22/05/12</td>
<td>V8</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>18/10/10</td>
<td>V7</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>25/05/10</td>
<td>V6</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>30/12/08</td>
<td>V5</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>20/09/07</td>
<td>V4</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>19/03/07</td>
<td>V3</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>26/02/07</td>
<td>V2</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Reviewed</td>
</tr>
<tr>
<td>10/05/04</td>
<td>V1</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Original approved version.</td>
</tr>
</tbody>
</table>